Current concepts and management approaches in nonalcoholic fatty liver disease

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Attar, Bashar M ^a   Van Thiel, David H ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Rush Oak Park Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; DIACYLGLYCEROL; FATTY ACID; METFORMIN; PIOGLITAZONE; PLACEBO; REACTIVE OXYGEN METABOLITE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID; ANTIDIABETIC AGENT;

BARIATRIC SURGERY; BLADDER CANCER; COFFEE; COGNITIVE THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE DURATION; EXERCISE; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY ACID OXIDATION; FLATULENCE; FOOD INTAKE; HUMAN; HYPERTRIGLYCERIDEMIA; INCONTINENCE; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; OBESITY; REVIEW; RISK FACTOR; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; DIET THERAPY; FATTY LIVER; KINESIOTHERAPY; RISK REDUCTION;

COGNITIVE THERAPY; DIET THERAPY; EXERCISE THERAPY; FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; RISK REDUCTION BEHAVIOR; THIAZOLIDINEDIONES;

EID: 84876522373     PISSN: 1537744X     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/481893     Document Type: Review

References (80)

1. Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G., A position statement on NAFLD/NASH based on the EASL 2009 special conference. Journal of Hepatology 2010 53 2 372 384 2-s2.0-77952529040 10.1016/j.jhep.2010. 04.008
2. Marcos A., Fisher R. A., Ham J. M., Olzinski A. T., Shiffman M. L., Sanyal A. J., Luketic V. A. C., Sterling R. K., Olbrisch M. E., Posner M. P., Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000 69 11 2410 2415 2-s2.0-0034659943 (Pubitemid 30409013)
3. Bellentani S., Saccoccio G., Masutti F., Crocè L. S., Brandi G., Sasso F., Cristanini G., Tiribelli C., Prevalence of and risk factors for hepatic steatosis in Northern Italy. Annals of Internal Medicine 2000 132 2 112 117 2-s2.0-0033982172 (Pubitemid 30044177)
4. Amarapurkar D., Kamani P., Patel N., Gupte P., Kumar P., Agal S., Baijal R., Lala S., Chaudhary D., Deshpande A., Prevalence of non-alcoholic fatty liver disease: population based study. Annals of Hepatology 2007 6 3 161 163 2-s2.0-35848932768 (Pubitemid 350277193)
5. Williams C. D., Stengel J., Asike M. I., Torres D. M., Shaw J., Contreras M., Landt C. L., Harrison S. A., Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011 140 1 124 131 2-s2.0-78650486196 10.1053/j.gastro.2010.09.038
6. Rahman R. N., Ibdah J. A., Nonalcoholic fatty liver disease without cirrhosis is an emergent and independent risk factor of hepatocellular carcinoma: a population based study. Hepatology 2012 56 241A
7. Lee J. Y., Kim K. M., Lee S. G., Yu E., Lim Y. S., Lee H. C., Chung Y. H., Lee Y. S., Suh D. J., Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. Journal of Hepatology 2007 47 2 239 244 2-s2.0-34347389654 10.1016/j.jhep.2007.02.007 (Pubitemid 47021248)
8. Adams L. A., Lymp J. F., St Sauver J., Sanderson S. O., Lindor K. D., Feldstein A., Angulo P., The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005 129 1 113 121 2-s2.0-22344452893 10.1053/j.gastro.2005.04.014 (Pubitemid 41002048)
9. Ong J. P., Pitts A., Younossi Z. M., Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. Journal of Hepatology 2008 49 4 608 612 2-s2.0-50549084740 10.1016/j.jhep.2008.06.018
10. Wong V. W. S., Hui A. Y., Tsang S. W. C., Chan J. L. Y., Wong G. L. H., Chan A. W. H., So W. Y., Cheng A. Y. S., Tong P. C. Y., Chan F. K. L., Sung J. J. Y., Chan H. L. Y., Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics 2006 24 8 1215 1222 2-s2.0-33748911973 10.1111/j.1365-2036.2006.03112.x (Pubitemid 44427509)
11. Hashimoto E., Yatsuji S., Tobari M., Taniai M., Torii N., Tokushige K., Shiratori K., Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Journal of Gastroenterology 2009 44 supplement 19 89 95 2-s2.0-58849090967 10.1007/s00535-008-2262-x
12. Hui A. Y., Wong V. W., Chan H. L., Histological progression of non-alcoholic fatty liver disease in Chinese patients. Alimentary Pharmacology & Therapeutics 2005 21 407 413 10.1111/j.1365-2036.2005.02334.x (Pubitemid 40313943)
13. Papatheodoridis G. V., Goulis J., Christodoulou D., Manolakopoulos S., Raptopoulou M., Andrioti E., Alexandropoulos N., Savvidou S., Papachristou A., Zervou E., Seferiadis K., Kousidou P., Vogiatzakis E., Tsianos E., High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity. European Journal of Gastroenterology and Hepatology 2007 19 4 281 287 2-s2.0-33947121228 10.1097/MEG.0b013e328011438b (Pubitemid 46412068)
14. Kallwitz E. R., Kumar M., Aggarwal R., Berger R., Layden-Almer J., Gupta N., Cotler S. J., Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Digestive Diseases and Sciences 2008 53 5 1358 1363 2-s2.0-41949127014 10.1007/s10620-008-0234-x
15. Yang L. Y., Kuksis A., Myher J. J., Steiner G., Origin of triacylglycerol moiety of plasma very low density lipoproteins in the rat: structural studies. Journal of Lipid Research 1995 36 1 125 136 2-s2.0-0028821066
16. Yamaguchi K., Yang L., McCall S., Huang J., Xing X. Y., Pandey S. K., Bhanot S., Monia B. P., Li Y. X., Diehl A. M., Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007 45 6 1366 1374 2-s2.0-34250356015 10.1002/hep.21655 (Pubitemid 46918320)
17. Day C. P., James O. F., Steatohepatitis: a tale of two 'hits'. Gastroenterology 1998 114 4 842 845 10.1016/S0016-5085(98)70599-2 (Pubitemid 28160420)
18. Day C. P., From fat to inflammation. Gastroenterology 2006 130 1 207 210 2-s2.0-30044431801 10.1053/j.gastro.2005.11.017 (Pubitemid 43049850)
19. Malhi H., Gores G. J., Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Seminars in Liver Disease 2008 28 4 360 369 2-s2.0-56649094325 10.1055/s-0028-1091980
20. Malhi H., Gores G. J., Lemasters J. J., Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 2006 43 2 S31 S44 2-s2.0-33644524120 10.1002/hep.21062
21. Li Z. Z., Berk M., McIntyre T. M., Feldstein A. E., Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. Journal of Biological Chemistry 2009 284 9 5637 5644 2-s2.0-65549136260 10.1074/jbc.M807616200
22. Carabelli J., Burgueño A. L., Rosselli M. S., Gianotti T. F., Lago N. R., Pirola C. J., Sookoian S., High fat diet-induced liver steatosis promotes an increase in liver mitochondrial biogenesis in response to hypoxia. Journal of Cellular and Molecular Medicine 2011 15 6 1329 1338 2-s2.0-78649618722 10.1111/j.1582-4934.2010.01128.x
23. Sookoian S., Gianotti T. F., Rosselli M. S., Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis 2011 218 2 378 385 10.1016/j.atherosclerosis.2011.05. 014
24. Jenkins C. M., Mancuso D. J., Yan W., Sims H. F., Gibson B., Gross R. W., Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. Journal of Biological Chemistry 2004 279 47 48968 48975 2-s2.0-10344262633 10.1074/jbc.M407841200 (Pubitemid 39625778)
25. Anderson N., Borlak J., Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacological Reviews 2008 60 3 311 357 2-s2.0-54049150442 10.1124/pr.108.00001
26. Díaz-Delfín J., Morales M., Caelles C., Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor γ by inhibition of the c-Jun NH2-terminal kinase pathway. Diabetes 2007 56 7 1865 1871 2-s2.0-34347369726 10.2337/db06-1293 (Pubitemid 47025460)
27. Bohinc B. N., Diehl A. M., Mechanisms of disease progression in NASH: new paradigms. Clinical Liver Disease 2012 16 3 549 565
28. Schwimmer J. B., Celedon M. A., Lavine J. E., Salem R., Campbell N., Schork N. J., Shiehmorteza M., Yokoo T., Chavez A., Middleton M. S., Sirlin C. B., Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009 136 5 1585 1592 2-s2.0-65249188812 10.1053/j.gastro.2009.01.050
29. Anstee Q. M., Daly A. K., Day C. P., Genetics of alcoholic and nonalcoholic fatty liver disease. Seminars in Liver Disease 2011 31 2 128 146 10.1055/s-0031-1276643
30. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L. A., Boerwinkle E., Cohen J. C., Hobbs H. H., Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics 2008 40 12 1461 1465 2-s2.0-56749096610 10.1038/ng.257
31. Kotronen A., Johansson L. E., Johansson L. M., Roos C., Westerbacka J., Hamsten A., Bergholm R., Arkkila P., Arola J., Kiviluoto T., Fisher R. M., Ehrenborg E., Orho-Melander M., Ridderstråle M., Groop L., Yki-Järvinen H., A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009 52 6 1056 1060 2-s2.0-67349174005 10.1007/s00125-009-1285-z
32. Sookoian S., Pirola C. J., Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011 53 6 1883 1894 2-s2.0-79957462315 10.1002/hep.24283
33. Bambha K., Belt P., Abraham M., Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012 55 3 769 780 10.1002/hep.24726
34. Speliotes E. K., Yerges-Armstrong L. M., Wu J., Hernaez R., Kim L. J., Palmer C. D., Gudnason V., Eiriksdottir G., Garcia M. E., Launer L. J., Nalls M. A., Clark J. M., Mitchell B. D., Shuldiner A. R., Butler J. L., Tomas M., Hoffmann U., Hwang S. J., Massaro J. M., O'Donnell C. J., Sahani D. V., Salomaa V., Schadt E. E., Schwartz S. M., Siscovick D. S., Voight B. F., Carr J. J., Feitosa M. F., Harris T. B., Fox C. S., Smith A. V., Kao W. H. L., Hirschhorn J. N., Borecki I. B., Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genetics 2011 7 3 2-s2.0-79953745343 10.1371/journal. pgen.1001324 e1001324
35. Speliotes E. K., Hernaez R., Feitosa M. F., Genetic variants predispose to nonalcoholic fatty liver disease across anestries. Hepatology 2012 56 4, supplement 242A
36. Yang Z., Wen J., Tao X., Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people. Molecular Biology Reports 2011 38 2 1145 1150 10.1007/s11033-010-0212-1
37. Chen C. H., Huang M. H., Yang J. C., Nien C. K., Yang C. C., Yeh Y. H., Yueh S. K., Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. Journal of Clinical Gastroenterology 2006 40 8 745 752 2-s2.0-33748457319 10.1097/00004836-200609000-00016 (Pubitemid 44350599)
38. Mouzaki M., Arendt B. M., Fischer S. E., Comelli E. M., Allard P., Assessment of intestinal microbiota in non-alcoholic fatty liver disease. Hepatology 2012 56 4, supplement 243A
39. Krasnoff J. B., Painter P. L., Wallace J. P., Bass N. M., Merriman R. B., Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2008 47 4 1158 1165 2-s2.0-42249114813 10.1002/hep.22137 (Pubitemid 351547902)
40. Perseghin G., Lattuada G., De Cobelli F., Ragogna F., Ntali G., Esposito A., Belloni E., Canu T., Terruzzi I., Scifo P., Del Maschio A., Luzi L., Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care 2007 30 3 683 688 10.2337/dc06-2032 (Pubitemid 46354353)
41. Mikines K. J., The influence of physical activity and inactivity on insulin action and secretion in man. Acta Physiologica Scandinavica, Supplement 1992 146 609 1 43 2-s2.0-0027031193 (Pubitemid 23018858)
42. Harrison S. A., Fecht W., Brunt E. M., Neuschwander-Tetri B. A., Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009 49 1 80 86 2-s2.0-58949102847 10.1002/hep.22575
43. Palmer M., Schaffner F., Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990 99 5 1408 1413 2-s2.0-0025186310 (Pubitemid 20381878)
44. Suzuki A., Lindor K., St Saver J., Lymp J., Mendes F., Muto A., Okada T., Angulo P., Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. Journal of Hepatology 2005 43 6 1060 1066 10.1016/j.jhep.2005. 06.008 (Pubitemid 41627993)
45. Ioannides Demos L., Piccenna L., McNeil J., Pharmacotherapies for obesity: past, current, and future therapies. Journal of Obesity 2011 2011 18 10.1155/2011/179674 179674
46. Wing R., Phelan S., Long-term weight loss maintenance. The American Journal of Clinical Nutrition 2005 82 222S 225S
47. Masheb R., Grilo C., Rolls B., A randomized controlled trial for obesity and binge eating disorder: low-energy- density dietary counseling and cognitivebehavioral therapy. Behaviour Research and Therapy 2011 49 12 821 829 10.1016/j.brat.2011.09.006
48. Ouyang X., Cirillo P., Sautin Y., McCall S., Bruchette J. L., Diehl A. M., Johnson R. J., Abdelmalek M. F., Fructose consumption as a risk factor for non-alcoholic fatty liver disease. Journal of Hepatology 2008 48 6 993 999 10.1016/j.jhep.2008.02.011
49. Kechagias S., Emersson A., Dahlqvist O., Lundberg P., Lindström T., Nystrom F. H., Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut 2008 57 5 649 654 2-s2.0-42549164262 10.1136/gut.2007.131797 (Pubitemid 351579979)
50. Shapiro A., Mu W., Roncal C., Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding. American Journal of Physiology 2008 295 5 R1370 R1375 10.1152/ajpregu.00195.2008
51. Bray G. A., Nielsen S. J., Popkin B. M., Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. American Journal of Clinical Nutrition 2004 79 4 537 543 2-s2.0-2142815151 (Pubitemid 41103894)
52. Lee S., Gura K. M., Puder M., Omega-3 fatty acids and liver disease. Hepatology 2007 45 4 841 845 2-s2.0-34247363143 10.1002/hep.21645 (Pubitemid 46631551)
53. Capanni M., Calella F., Biagini M. R., Genise S., Raimondi L., Bedogni G., Svegliati-Baroni G., Sofi F., Milani S., Abbate R., Surrenti C., Casini A., Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Alimentary Pharmacology & Therapeutics 2006 23 8 1143 1151 10.1111/j.1365-2036.2006.02885.x (Pubitemid 43779354)
54. Tanaka N., Sano K., Horiuchi A., Tanaka E., Kiyosawa K., Aoyama T., Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. Journal of Clinical Gastroenterology 2008 42 4 413 418 2-s2.0-41349102802 10.1097/MCG.0b013e31815591aa (Pubitemid 351450629)
55. Xu J., Cho H., O'Malley S., Park J. H. Y., Clarke S. D., Dietary polyunsaturated fats regulate rat liver sterol regulatory element binding proteins-1 and -2 in three distinct stages and by different mechanisms. Journal of Nutrition 2002 132 11 3333 3339 2-s2.0-0036846040 (Pubitemid 35304240)
56. Houglum K., Venkataramani A., Lyche K., Chojkier M., A pilot study of the effects of d- α -tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997 113 4 1069 1073 2-s2.0-0030854425 10.1053/gast.1997.v113.pm9322499 (Pubitemid 27418958)
57. Sanyal A. J., Chalasani N., Kowdley K. V., Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England Journal of Medicine 2010 362 1675 1685 10.1056/NEJMoa0907929
58. Lavine J. E., Schwimmer J. B., Van Natta M. L., Molleston J. P., Murray K. F., Rosenthal P., Abrams S. H., Scheimann A. O., Sanyal A. J., Chalasani N., Tonascia J., Ünalp A., Clark J. M., Brunt E. M., Kleiner D. E., Hoofnagle J. H., Robuck P. R., Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011 305 16 1659 1668 2-s2.0-79955446251 10.1001/jama.2011.520
59. Miller E. R. III, Pastor-Barriuso R., Dalal D., Riemersma R. A., Appel L. J., Guallar E., Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine 2005 142 1 37 46 2-s2.0-19944427642
60. Klein E. A., Thompson I. M., Tangen C. M., Vitamin E and the risk of prostate cancer. The selenium and vitamin E cancer prevention trial (SELECT). JAMA 2011 306 14 1549 1556 10.1001/jama.2011.1437
61. Chalasani N., Younossi Z., Lavine J. E., The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012 55 6 2005 2023
62. Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N., David E., Rizzetto M., Marchesini G., A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. American Journal of Gastroenterology 2005 100 5 1082 1090 2-s2.0-19144365586 10.1111/j.1572-0241.2005.41583.x (Pubitemid 40769045)
63. Haukeland J. W., Konopski Z., Eggesbø H. B., Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scandinavian Journal of Gastroenterology 2009 44 7 853 860 10.1080/ 00365520902845268
64. Vernon G., Baranova A., Younossi Z. M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology and Therapeutics 2011 34 3 274 285 2-s2.0-79960029926 10.1111/j.1365-2036.2011. 04724.x
65. Yki-Jarvinen H., Thiazolidinediones. The New England Journal of Medicine 2004 351 1106 1118 10.1056/NEJMra041001 (Pubitemid 39167514)
66. Boettcher E., Csako G., Pucino F., Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 2012 35 1 66 75 10.1111/j.1365-2036. 2011.04912.x
67. Klatsky A. L., Morton C., Udaltsova N., Friedman G. D., Coffee, cirrhosis, and transaminase enzymes. Archives of Internal Medicine 2006 166 11 1190 1195 2-s2.0-33745038932 10.1001/archinte.166.11.1190 (Pubitemid 43877627)
68. Birerdinc A., Stepanova M., Pawloski L., Younossi Z. M., Caffeine is protective in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2012 35 1 76 82 10.1111/j.1365-2036.2011.04916.x
69. Kalthoff S., Ehmer U., Freiberg N., Manns M. P., Strassburg C. P., Coffee induces expression of glucuronosyl transferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology 2010 139 5 1699 1710 2-s2.0-77958093867 10.1053/j.gastro.2010.06.048
70. Gressner O. A., Less Smad2 is good for you! A scientific update on coffee's liver benefits. Hepatology 2009 50 3 970 978 2-s2.0-70349241723 10.1002/hep.23097
71. Crozier T. W., Stalmach A., Lean M. E., Crozier A., Espresso coffees, caffeine and chlorogenic acid intake: potential health implications. Food & Function 2012 3 30 33 10.1039/c1fo10240k
72. Molloy J. W., Calcagno C. J., Williams C. D., Jones F. J., Torres D. M., Harrison S. A., Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012 55 2 429 436 10.1002/hep.24731
73. Anty R., Marjoux S., Iannelli A., Patouraux S., Schneck A. S., Bonnafous S., Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. Journal of Hepatology 2012 57 5 1090 1096 10.1016/j.jhep.2012.07.014
74. Modi A. A., Feld J. J., Park Y., Kleiner D. E., Everhart J. E., Liang T. J., Hoofnagle J. H., Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010 51 1 201 209 2-s2.0-73449136857 10.1002/hep.23279
75. Costentin C. E., Roudot-Thoraval F., Zafrani E. S., Medkour F., Pawlotsky J. M., Mallat A., Hézode C., Association of caffeine intake and histological features of chronic hepatitis C. Journal of Hepatology 2011 54 6 1123 1129 10.1016/j.jhep.2010.08.027
76. Buchwald H., Avidor Y., Braunwald E., Jensen M. D., Pories W., Fahrbach K., Schoelles K., Bariatric surgery: a systematic review and meta-analysis. JAMA 2004 292 14 1724 1737 2-s2.0-5044242948 10.1001/jama.292.14.1724 (Pubitemid 39346675)
77. Mummadi R. R., Kasturi K. S., Chennareddygari S., Sood G. K., Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clinical Gastroenterology and Hepatology 2008 6 12 1396 1402 2-s2.0-57149101692 10.1016/j.cgh.2008.08.012
78. Neuschwander-Tetri B. A., Lifestyle modification as the primary treatment of NASH. Clinics in Liver Disease 2009 13 4 649 665 2-s2.0-70349765667 10.1016/j.cld.2009.07.006
79. Scaglioni F., Ciccia S., Marino M., Bedogni G., Bellentani S., ASH and NASH. Digestive Diseases 2011 29 2 202 210 10.1159/000323886
80. Ramesh S., Sanyal A. J., Evaluation and management of non-alcoholic steatohepatitis. Journal of Hepatology 2005 42 S2 S12 10.1016/j.jhep.2004.11.022 (Pubitemid 40364599)